TY - JOUR
T1 - Therapeutic roles of PPARα activation in ocular ischemic diseases
AU - Lee, Deokho
AU - Tomita, Yohei
AU - Negishi, Kazuno
AU - Kurihara, Toshihide
N1 - Funding Information:
This review article was supported by Grants-in-Aid for Scientific Research (KAKENHI, number 15K10881, and 18K09424) f r om t he Mi ni st r y of Educat i on, Cul t ur e, Spor t s, Sci ence, and Technol ogy ( MEXT) t o T. K. and by JST SPRI NG ( number JPMJSP2123) to D.L. Moreover, Y.T. was funded by the Manpei Suzuki Diabetes Foundation, the Alcon Research Institute, and the Bert M. Glaser, MD Award.
Funding Information:
Acknowledgements. This review article was supported by Grants-in-Aid
Publisher Copyright:
© The Author(s) 2023.
PY - 2023/4
Y1 - 2023/4
N2 - Ocular ischemia is one of the leading causes of blindness. It is related to various ocular diseases and disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma, and corneal injury. Ocular ischemia occurs due to an abnormal supply of oxygen and nutrients to the eye, resulting in ocular metabolic dysfunction. These changes can be linked with pathologic conditions in the eye, such as inflammation, neovascularization, and cell death, ultimately leading to vision loss. The current treatment care for ocular ischemia is limited. Peroxisome proliferator-activated recept or α (PPARα) i s a nucl ear recept or prot ei n functioning in regulating lipid metabolism, fatty acid oxidation, and glucose homeostasis. Recently, PPARα activation has been suggested as a useful therapeutic t arget i n t r eat i ng ocul ar i schemi a. However, i t s applications have not been well summarized. In this review, we cover an overview of the therapeutic roles of PPARα activation in various ocular ischemic conditions with recent experimental evidence and further provide clinical implications of its therapeutic applications. Our review will enable more approaches to comprehensively understand the therapeutic roles of PPARα activation for preventing ocular ischemic diseases.
AB - Ocular ischemia is one of the leading causes of blindness. It is related to various ocular diseases and disorders, including age-related macular degeneration, diabetic retinopathy, glaucoma, and corneal injury. Ocular ischemia occurs due to an abnormal supply of oxygen and nutrients to the eye, resulting in ocular metabolic dysfunction. These changes can be linked with pathologic conditions in the eye, such as inflammation, neovascularization, and cell death, ultimately leading to vision loss. The current treatment care for ocular ischemia is limited. Peroxisome proliferator-activated recept or α (PPARα) i s a nucl ear recept or prot ei n functioning in regulating lipid metabolism, fatty acid oxidation, and glucose homeostasis. Recently, PPARα activation has been suggested as a useful therapeutic t arget i n t r eat i ng ocul ar i schemi a. However, i t s applications have not been well summarized. In this review, we cover an overview of the therapeutic roles of PPARα activation in various ocular ischemic conditions with recent experimental evidence and further provide clinical implications of its therapeutic applications. Our review will enable more approaches to comprehensively understand the therapeutic roles of PPARα activation for preventing ocular ischemic diseases.
KW - Fenofibrate
KW - Fibroblast growth factor 21 (FGF21)
KW - Ocular ischemia
KW - Pemafibrate
KW - Peroxisome proliferator-activated receptor α (PPARα)
UR - http://www.scopus.com/inward/record.url?scp=85146279825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146279825&partnerID=8YFLogxK
U2 - 10.14670/HH-18-542
DO - 10.14670/HH-18-542
M3 - Review article
C2 - 36305579
AN - SCOPUS:85146279825
SN - 0213-3911
VL - 38
SP - 391
EP - 401
JO - Histology and Histopathology
JF - Histology and Histopathology
IS - 4
ER -